KYTX vs NVS
KYTX: Kyverna Therapeutics is a late-stage clinical company developing potentially curative CAR T-cell therapies for patients with severe neurologic autoimmune diseases. NVS: Novartis is a leading global pharmaceutical company focused on discovering and developing innovative, high-efficacy medicines across oncology, immunology, and neuroscience.
Side-by-side fundamentals
| Metric | KYTX | NVS | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $5.84 | $153.93 | |
| Market cap | $361M | $286.6B | |
| ROE FY2025, SEC XBRL | -69.4% | +30.0% | NVS higher |
| ROA FY2025, SEC XBRL | -54.9% | +12.6% | NVS higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.15 | n/a | |
| Dividend yield as of 2026-09-03 | n/a | +3.4% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-02 | 1.76 | 0.22 | |
| 1-year return as of 2026-10-21 close | -18.2% | +17.2% | NVS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.